comprehensive -WSS

comprehensive

author：hotspot 2025-09-27 22:59:26 - browse：9

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Fentanyl is making it harder to start addiction treatment

entertainment

WSS

Questions and answers about ramping up H5N1 bird flu vaccine

6 solutions to address cancer drug shortages and others

Questions and answers about ramping up H5N1 bird flu vaccine

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Experts study whether long Covid risk adds up with each reinfection

Setback for rare diseases as Taysha Gene Therapies pulls back

focus

comprehensive

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Guidelines to prevent youth baseball injuries need more muscle

Lawsuit highlights wrinkle for disputes over surprise medical bills

Tori Bowie and the unacceptable rates of Black maternal death

Reports of telehealth's death have been greatly exaggerated

The cancer drug shortage isn’t new — and neither are the solutions

Will an HIV vaccine ever be a reality?

Wildfire smoke exposes gaps in outdoor worker protections

Medicare innovation center doesn’t save money, experts say

hotspot

2023 Nobel Prize in Medicine goes to Karikó and Weissman

CDC picks Alphabet's Verily for wasterwater surveillance contract

H5N1 bird flu outbreak: Second human case reported, in Michigan

Making the case for fair compensation in clinical trials

Lawsuit highlights wrinkle for disputes over surprise medical bills

Addressing health care workers' trauma can help fight burnout

explore

hotspot

entertainment

entertainment